Effect of Pioglitazone on Cardiovascular Outcome on Higashi-Saitama Trial in Patients With Type 2 Diabetes
Overview
We want to investigate the effects of pioglitazone on cardiovascular events in Japanese patients with type 2 diabetes.
Study Type
- Study Type: Observational
- Study Design
- Time Perspective: Prospective
Detailed Description
Primary composite endpoints: Cardiovascular death Non-fatal myocardial infarction and angina Non-fatal stroke Renal failure (hemodialysis/doubling of serum creatinine) Secondary endpoints: urinary albumin excretion diabetic retinopathy hyperlipidemia hypertension gout
Interventions
- Drug: pioglitazone
Participating in This Clinical Trial
Inclusion Criteria
- type 2 diabetes HbA1c: more than 7% and less than 9% Exclusion Criteria:
- insulin treatment
Gender Eligibility: All
Minimum Age: 20 Years
Maximum Age: 70 Years
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- Dokkyo Medical University
- Overall Official(s)
- Yoshimasa Aso, MD, Principal Investigator, Dokkyo Medical University, Koshigaya Hospital
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.